We have 15+ years of experience with Methoxy Polyethylene Glycol (mPEG) and activated mPEG development and manufacturing. We perform mPEG development at our R and D center in Hyderabad. Our team has extensive experience in synthesis, analysis, purification and troubleshooting of mPEG derivatives and have technical capabilities in synthetic route design to incorporate various activating groups and help customize products as per end applications.
Aurigene is a leading manufacturer and supplier of Methoxy Polyethylene Glycol (mPEGs) and activated Methoxy Polyethylene Glycol (mPEGs) which are used for the conjugation of proteins, antibody fragments and peptides. With our GMP manufacturing capabilities and backward integration to highly pure Methoxy PEG-OH, we guarantee the quality and security of the supplies of our activated Methoxy PEGs (mPEGs) products.
As a leading CDMO, we understand customer requirements and customize our products to meet the client’s requirements. Currently, we serve multiple customers in various products such as diagnostic players, other mPEG suppliers, and big pharma using mPEG for advanced therapeutics. In addition, our backward integration of key raw materials makes it possible to ensure a sustainable quality of the final activated mPEG throughout the manufacturing process.
We have technical capabilities in synthetic route design to incorporate the activating group and help customize products as per end applications. Our centers at Hyderabad and Mirfield are equipped with advanced instruments to enable the scale-up of activated mPEG production up to 90 kg per batch.
Successful custom PEGylation requires several factors to be optimized such as the site of PEGylation, chain length, and mPEG linkers. Determining the optimum mPEG may require the testing of several activated mPEGs at different chain lengths. We offer a range of activated linear mPEGs to enable our customers to find the ideal mPEG for conjugation of the required quality, with high levels of activation, narrow polydispersity and low diol content.
mPEG-OH is the key raw material for the synthesis of activated PEGs. Our backward integration of key raw materials makes it possible to ensure a sustainable quality of the final activated mPEG throughout the manufacturing process. Our process to make high quality pharmaceutical grade mPEG-OH is patent protected. We manufacture mPEG alcohols in our Cuernavaca, Mexico site.
We support the production of mPEG-OH of molecular weight ranging from 2kDa, 5kDa, 10kDa, 20kDa, 30kDa, 40kDa, and 50kDa.
We are specialists in liner-activated mPEG. Our range of products includes various activating groups such as
We support the production of mPEG derivatives of molecular weight ranging from 2kDa, 5kDa, 10kDa, 20kDa, 30kDa, 40kDa, and 50kDa.
We help aid our customers with supplies for their development and clinical purposes. We manufacture mPEG derivatives from our Mirfield, UK and Hyderabad, India sites. Key features of our sites are as below:
The analysis of large polymeric materials such as PEGs can be challenging. Our analytical lab is equipped with advanced equipment and analytical instruments to determine the quality of our highly pure mPEGs.
Also, we have a highly experienced analytical team who can characterize the compounds for any required impurity specifications and develop as well as validate such methods.
We perform all critical analytical tests in-house such as:
Technical know-how to deliver the most challenging specifications
Experience and legacy of working with big pharma clients
Analytical capabilities
US FDA audited facilities
Backward integration of mPEG alcohol
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
PROteolysis TArgeting Chimeras (PROTAC) are a series of hetero-bifunctional molecules that hijack the body’s natural disposal system to initiate selective degradation of the protein of interest (POI). They are generally bifunctional molecules that hijack the Ubiquitin Proteasome System (UPS) to achieve the total degradation of a disease-related target protein. ...
Read MorePeptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds....
Read MoreAurigene Pharmaceutical Services off end-to-end formulation development and manufacturing services fm pr-formulations, clinical development, clinical supplies to commercial manufacturing. ...
Read MoreChallenges: The evaluation of Evans Blue Dye (EBD) by fluorescence measurements of cryosections of individual muscle sections, and its quantification by auto fluorescence is a laborious and time-consuming process. Study design: Both sham and thermal injury techniques were followed. The evaluation of EBD was done to assess the effectiveness of two compounds in the...
Read More2016
The 7H-indolo[30 ,20 :4,5]furo[2,3-b]quinoxaline derivatives are synthesized directly from methyl 2-(2- chloro-1H-indol-3-yl)-2-oxoacetate or its N-alkyl derivatives under neutral or mildly acidic conditions. This new one-pot methodology was found to be general and greener as it avoids the use of environmentally harmful POCl3 and strong alkali required for the pr...
Read More2005
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More2005
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More2005
Bromelain is a complex natural mixture of proteolytic enzymes derived from pineapple (Ananas cosmosus), which has good therapeutic properties. Bromelain can be found in all tissues of pineapple plants, including the stem, fruit, and leaves. Bromelain plays an important role in the treatment of many diseases such as soft tissue inflammation and edema, deep derma, ...
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market